Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

(2023) Shai Shimony et al.   AMERICAN JOURNAL OF HEMATOLOGY

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

(2023) Hua Jin et al.   Journal of Hematology & Oncology

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

(2022) Jayastu Senapati et al.   AMERICAN JOURNAL OF HEMATOLOGY

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

(2022) Zheng Li et al.   Frontiers in Oncology

Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel

(2022) Hartmut Döhner et al.   BLOOD

Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?

(2022) Prajwal Dhakal et al.   BLOOD REVIEWS

Core binding factor acute myelogenous leukemia-2021 treatment algorithm

(2021) Gautam Borthakur et al.   Blood Cancer Journal

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

(2020) Abhishek Maiti et al.   HAEMATOLOGICA

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemia

(2020) Shukaib Arslan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

(2016) N. Duployez et al.   BLOOD

The genomic landscape of core-binding factor acute myeloid leukemias

(2016) Zachary J Faber et al.   NATURE GENETICS

Epigenetic silencing of Bcl-2, CEBPA and p14ARF by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line

(2013) WEN-YUE ZHUANG et al.   ONCOLOGY REPORTS

The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO

(2012) F.-S. Chou et al.   BLOOD